Literature DB >> 16585549

Targeted disruption of CD38 accelerates autoimmune diabetes in NOD/Lt mice by enhancing autoimmunity in an ADP-ribosyltransferase 2-dependent fashion.

Jing Chen1, Yi-Guang Chen, Peter C Reifsnyder, William H Schott, Chul-Ho Lee, Melissa Osborne, Felix Scheuplein, Friedrich Haag, Friedrich Koch-Nolte, David V Serreze, Edward H Leiter.   

Abstract

Ubiquitously expressed CD38 and T cell-expressed ADP-ribosyltransferase 2 (ART2) are ectoenzymes competing for NAD substrate. CD38 exerts pleiotropic actions in hemopoietic and nonhemopoietic compartments via effects on calcium mobilization. ART2 is an ADP-ribosyltransferase on naive CD4+ and CD8+ T cells. ART2-catalyzed ADP-ribosylation of the P2X7 purinoreceptor elicits apoptosis. Transfer of a genetically disrupted CD38 allele into the autoimmune diabetes-prone NOD/Lt background accelerated diabetes onset in both sexes, whereas transfer of a disrupted ART2 complex had no effect. However, the fact that the accelerated pathogenesis mediated by CD38 deficiency required ART2 activity was demonstrated by combining both ART2 and CD38 deficiencies. Reciprocal bone marrow reconstitution studies demonstrated accelerated diabetes only when CD38-deficient bone marrow was transferred into CD38-deficient recipients. Neither decreases in beta cell function nor viability were indicated. Rather, the balance between T-effectors and T-regulatory cells was disturbed in CD38-deficient but ART2-intact NOD mice. In these mice, significant reductions in total viable CD8+ T cells were observed. This was accompanied by an age-dependent increase in a diabetogenic CD8 clonotype. This in turn correlated with impaired T-regulatory development (10-fold reduction in Foxp3 mRNA expression). These changes were corrected when CD38 deficiency was combined with ART2 deficiency. Both ART2-deficient and CD38/ART2 combined deficient T cells were resistant to NAD-induced killing in vitro, whereas CD38-deficient but ART2-intact T cells showed increased sensitivity, particularly the CD4+ CD25+ subset. Unexpectedly, diabetes development in the combined CD38/ART2 stock was strongly suppressed, possibly through epistatic interactions between genes linked to the targeted CD38 on Chromosome 5 and the ART2 complex on Chromosome 7.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16585549     DOI: 10.4049/jimmunol.176.8.4590

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  30 in total

Review 1.  Nanospaces between endoplasmic reticulum and mitochondria as control centres of pancreatic β-cell metabolism and survival.

Authors:  James D Johnson; Michael J Bround; Sarah A White; Dan S Luciani
Journal:  Protoplasma       Date:  2011-11-22       Impact factor: 3.356

Review 2.  Signaling properties of CD38 in the mouse immune system: enzyme-dependent and -independent roles in immunity.

Authors:  Frances E Lund
Journal:  Mol Med       Date:  2006 Nov-Dec       Impact factor: 6.354

Review 3.  The Purinergic System as a Pharmacological Target for the Treatment of Immune-Mediated Inflammatory Diseases.

Authors:  Luca Antonioli; Corrado Blandizzi; Pál Pacher; György Haskó
Journal:  Pharmacol Rev       Date:  2019-07       Impact factor: 25.468

4.  A candidate gene for autoimmune myasthenia gravis.

Authors:  Guida Landouré; Melanie A Knight; Horia Stanescu; Addis A Taye; Yijun Shi; Oumarou Diallo; Janel O Johnson; Dena Hernandez; Bryan J Traynor; Leslie G Biesecker; Abdel Elkahloun; Carlo Rinaldi; Angela Vincent; Nick Willcox; Robert Kleta; Kenneth H Fischbeck; Barrington G Burnett
Journal:  Neurology       Date:  2012-06-27       Impact factor: 9.910

Review 5.  Roles and mechanisms of the CD38/cyclic adenosine diphosphate ribose/Ca(2+) signaling pathway.

Authors:  Wenjie Wei; Richard Graeff; Jianbo Yue
Journal:  World J Biol Chem       Date:  2014-02-26

6.  CD38, CD81 and BAFFR combined expression by transitional B cells distinguishes active from inactive systemic lupus erythematosus.

Authors:  Ana Henriques; Isabel Silva; Luís Inês; M Margarida Souto-Carneiro; M Luísa Pais; Hélder Trindade; José António Pereira da Silva; Artur Paiva
Journal:  Clin Exp Med       Date:  2015-04-18       Impact factor: 3.984

7.  Targeting CD38 Suppresses Induction and Function of T Regulatory Cells to Mitigate Immunosuppression in Multiple Myeloma.

Authors:  Xiaoyan Feng; Li Zhang; Chirag Acharya; Gang An; Kenneth Wen; Lugui Qiu; Nikhil C Munshi; Yu-Tzu Tai; Kenneth C Anderson
Journal:  Clin Cancer Res       Date:  2017-03-01       Impact factor: 12.531

8.  Testing the role of P2X7 receptors in the development of type 1 diabetes in nonobese diabetic mice.

Authors:  Yi-Guang Chen; Felix Scheuplein; John P Driver; Amanda A Hewes; Peter C Reifsnyder; Edward H Leiter; David V Serreze
Journal:  J Immunol       Date:  2011-02-25       Impact factor: 5.422

9.  Emerging functions of extracellular pyridine nucleotides.

Authors:  Richard A Billington; Santina Bruzzone; Antonio De Flora; Armando A Genazzani; Friedrich Koch-Nolte; Mathias Ziegler; Elena Zocchi
Journal:  Mol Med       Date:  2006 Nov-Dec       Impact factor: 6.354

10.  Type 1 diabetes immunotherapy using polyclonal regulatory T cells.

Authors:  Jeffrey A Bluestone; Jane H Buckner; Mark Fitch; Stephen E Gitelman; Shipra Gupta; Marc K Hellerstein; Kevan C Herold; Angela Lares; Michael R Lee; Kelvin Li; Weihong Liu; S Alice Long; Lisa M Masiello; Vinh Nguyen; Amy L Putnam; Mary Rieck; Peter H Sayre; Qizhi Tang
Journal:  Sci Transl Med       Date:  2015-11-25       Impact factor: 17.956

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.